🔍

NIVABUPA - Niva Bupa Health

📊 NSE: NIVABUPA 🏢 Finance & Investments 📅 Last Updated: 12/14/2025 10:34

📢 Recent Corporate Announcements

IRDAI Approves Transfer of 14.62 Crore Equity Shares by Fettle Tone LLP in Niva Bupa

🔵 WATCH ⭐ 7/10

REGULATORY 📅 10 Apr 2026, 03:50 PM

Niva Bupa Health Insurance has received formal approval from the IRDAI for the transfer of up to 14,62,02,091 equity shares. The shares are being transferred by Fettle Tone LLP, an existing investor in the company. This regulatory clearance follows the provisions of the Insurance Act, 1938, and the updated 2024 IRDAI regulations regarding capital structure and share transfers. The move indicates a potential change in the shareholding pattern or an exit/partial exit by a significant investor.

IRDAI approved the transfer of up to 14,62,02,091 equity shares by Fettle Tone LLP.
The approval was granted under Section 6A of the Insurance Act, 1938.
The transaction complies with IRDAI (Registration, Capital Structure, Transfer of Shares and Amalgamation of Insurers) Regulations, 2024.
Fettle Tone LLP is an existing investor, and this transfer represents a significant volume of the company's equity.

💡 Investors should monitor the identity of the buyer and the transaction price to assess institutional sentiment. While this is a secondary transfer and doesn't dilute equity, a change in major stakeholders can influence long-term strategy.

Niva Bupa Submits SEBI Regulation 74(5) Compliance Certificate for Q4 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 09 Apr 2026, 02:45 PM

Niva Bupa Health Insurance has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations for the period ending March 31, 2026. The company's Registrar and Share Transfer Agent, KFin Technologies, confirmed that no dematerialization requests were received during this quarter. This is because the company maintains its shareholding entirely in electronic form, with zero shares held in physical mode. This filing is a standard procedural requirement for all listed entities in India.

Compliance certificate submitted for the quarter ended March 31, 2026.
Registrar KFin Technologies confirmed zero demat requests were processed during the period.
The filing confirms that no shares of Niva Bupa are held in physical mode.
The document was officially signed and submitted on April 09, 2026.

💡 No action is required as this is a routine regulatory filing. Investors should focus on the company's upcoming quarterly financial results for material performance updates.

Niva Bupa to Close Trading Window from April 1, 2026, for FY26 Financial Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 30 Mar 2026, 05:10 PM

Niva Bupa Health Insurance has announced the closure of its trading window starting April 1, 2026, in compliance with SEBI Insider Trading regulations. This closure is ahead of the announcement of audited financial results for the quarter and full financial year ending March 31, 2026. The window will remain closed for all designated persons and their immediate relatives. It is scheduled to reopen 48 hours after the financial results are officially disclosed to the exchanges.

Trading window closure commences on Wednesday, April 1, 2026.
Closure pertains to the audited financial results for the quarter and year ending March 31, 2026.
The window will reopen 48 hours after the results become generally available information.
The specific date for the Board Meeting to approve results will be announced in due course.

💡 This is a routine regulatory announcement with no impact on company fundamentals. Investors should monitor for the upcoming board meeting date to review the FY26 financial performance.

Niva Bupa Shareholders Approve CEO Remuneration Revision and New Director Appointment

🟡 NEUTRAL ⭐ 6/10

MANAGEMENT 📅 27 Mar 2026, 06:08 PM

Niva Bupa Health Insurance has successfully passed two key resolutions via postal ballot with near-unanimous shareholder support. The appointment of Mr. Roger William John Davis as a Non-Executive Director was approved with 99.99% of the votes. Furthermore, shareholders greenlit a revision in the remuneration for MD & CEO Krishnan Ramachandran for the 2025-26 financial year. The high approval ratings reflect strong investor confidence in the company's leadership and strategic direction.

Appointment of Roger William John Davis as Non-Executive Director approved with 99.99% votes in favor.
Remuneration revision for MD & CEO Krishnan Ramachandran for FY 2025-26 passed with 99.99% majority.
Total valid votes cast for the CEO remuneration resolution amounted to 1,56,61,12,697.
The postal ballot process concluded on March 26, 2026, with results officially declared on March 27, 2026.

💡 Investors should view the high approval rates as a sign of management stability and strong institutional backing. No immediate action is required as these are standard governance approvals.

Niva Bupa to Participate in ICICI Securities Investor Meet on March 30, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 24 Mar 2026, 06:01 PM

Niva Bupa Health Insurance Company Limited has announced its participation in a group investor interaction scheduled for March 30, 2026. The meeting is organized by ICICI Securities and will be held at the Grand Hyatt in Mumbai. This event is part of the company's routine engagement with institutional investors and analysts. The company has explicitly stated that no unpublished price sensitive information will be shared during this interaction.

Investor meeting scheduled for Monday, March 30, 2026, in Mumbai.
The interaction is organized by ICICI Securities as a group meet.
Company representatives will engage with analysts and institutional investors.
Compliance confirmed with Regulation 30 of SEBI (LODR) Regulations, 2015.
Explicit confirmation that no unpublished price sensitive information (UPSI) will be disclosed.

💡 Investors should monitor for any investor presentations or transcripts released after the meeting for insights into management's outlook. No immediate portfolio action is required based on this routine disclosure.

Niva Bupa Receives ₹28.37 Crore Income Tax Demand for AY 2023-24

🔴 NEGATIVE ⭐ 6/10

LEGAL 📅 15 Mar 2026, 12:57 PM

Niva Bupa Health Insurance has received an Order cum Notice of Demand from the Income Tax Department totaling ₹28.37 crore for the Assessment Year 2023-24. The demand includes a principal tax amount and an interest component of ₹7.10 crore. The dispute arises from the disallowance of certain marketing expenses and provisions for claims Incurred But Not Reported (IBNR). The company intends to contest this demand through an appeal, noting that these issues are largely industry-wide accounting matters.

Total income tax demand of ₹28,37,45,380 received for Assessment Year 2023-24
Demand includes an interest component of ₹7,10,47,664 under Section 156 of the IT Act
Dispute involves disallowance of marketing expenses under Section 37(1) and IBNR/IBNER claim provisions
Company plans to exercise its right to appeal before the Appellate Authorities
Management characterizes the disallowances as industry-wide issues rather than company-specific failures

💡 Investors should monitor the outcome of the appeal as it pertains to standard insurance accounting practices. While the demand is a negative development, the company's intent to appeal suggests no immediate cash outflow impact.

Niva Bupa Allots 2.58 Lakh Equity Shares Under ESOP Scheme 2020

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 05 Mar 2026, 06:36 PM

Niva Bupa Health Insurance Company Limited has announced the allotment of 2,58,200 equity shares on March 05, 2026. These shares were issued to eligible employees who exercised their options under the company's Employee Stock Option Plan 2020 (ESOP Scheme 2020). The new shares carry a face value of ₹10 each and will rank pari-passu with the existing equity shares. This is a routine corporate action that results in a marginal increase in the company's total paid-up share capital.

Allotment of 2,58,200 equity shares to eligible employees under ESOP Scheme 2020
Each share has a face value of ₹10 and ranks equally with existing shares
Allotment date confirmed as March 05, 2026
The issuance follows the exercise of options by eligible grantees

💡 This is a routine administrative update with negligible impact on share value. No specific action is required from investors.

Niva Bupa Receives IRDAI Show Cause Notice and Letter of Advice for Regulatory Violations

🔵 WATCH ⭐ 6/10

REGULATORY 📅 27 Feb 2026, 04:29 PM

Niva Bupa Health Insurance received a Show Cause Notice (SCN) and a Letter of Advice from IRDAI on February 26, 2026, following an inspection conducted in February 2025. The regulatory communication highlights alleged violations of Master Circulars regarding Health Insurance Business, Policyholder Protection, and Corporate Governance. While the company maintains there is no immediate financial or operational impact, it is currently drafting a response to the SCN. Investors should track this development to see if it results in future penalties or stricter regulatory oversight.

IRDAI issued a Show Cause Notice and Letter of Advice on February 26, 2026, regarding business and operational aspects.
Alleged non-compliances relate to Master Circulars on Health Insurance Business, Protection of Policyholders Interest, and Corporate Governance.
The company stated there is no quantifiable financial impact on operations or activities at this stage.
Niva Bupa is in the process of submitting a response to IRDAI and implementing advised compliance measures.

💡 Investors should stay cautious and await the final resolution of the Show Cause Notice to assess potential long-term regulatory risks or penalties. Monitor if these compliance measures lead to increased operational costs or changes in business strategy.

Niva Bupa to Attend Kotak Securities Chasing Growth 2026 Conference on February 24

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 16 Feb 2026, 05:44 PM

Niva Bupa Health Insurance Company Limited has announced its participation in the 'Kotak Securities - Chasing Growth 2026 Conference' scheduled for February 24, 2026. The event will be held in Mumbai and involves interactions with various institutional investors and analysts. This disclosure is a routine compliance filing under Regulation 30 of SEBI (LODR) Regulations. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during the conference.

Participation in Kotak Securities - Chasing Growth 2026 Conference confirmed for Feb 24, 2026.
The meeting is scheduled to take place in Mumbai as a physical conference.
Compliance filing under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Company confirms that no unpublished price sensitive information (UPSI) will be disclosed during the event.

💡 Investors should monitor the company's website or exchange filings after the event for any investor presentations or transcripts that may provide insights into the company's growth outlook. No immediate trading action is required based on this routine scheduling announcement.

Niva Bupa Q3 FY26: 9M PAT Jumps 74% to ₹208 Cr; Retail Market Share Hits 10%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 03 Feb 2026, 05:18 PM

Niva Bupa reported a robust financial performance for the nine months ended December 31, 2025, with Profit After Tax (PAT) increasing 74% YoY to ₹208 crores. The company achieved a retail growth rate of 33%, pushing its retail market share to 10%. Operational efficiency improved as the Expense of Management (EOM) ratio dropped to 35% from 39% YoY, while the combined ratio improved by 50 bps to 102.9%. Despite a ₹20 crore one-off impact from new wage codes, the company maintained a strong solvency ratio of 2.49.

9M PAT surged 74% YoY to ₹208 crores, with Q3 PAT standing at ₹77 crores.
Retail health insurance segment grew by 33% in the 9-month period, with Q3 new business growth at 46%.
Combined Ratio (IFRS) improved by 50 basis points to 102.9% for the 9-month period.
Direct digital channel business witnessed a significant growth of 70% in Q3 FY26.
Solvency ratio remains healthy at 2.49, providing significant cushion for future growth.

💡 Investors should take note of the strong retail growth and improving operating leverage which are driving profitability. The company's ability to gain market share while improving its combined ratio suggests a sustainable growth trajectory.

Niva Bupa Releases Audio Recording of Q3 & 9M FY26 Earnings Conference Call

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 29 Jan 2026, 10:38 PM

Niva Bupa Health Insurance Company Limited has officially released the audio recording of its earnings conference call held on January 29, 2026. The call addressed the company's financial and operational performance for the third quarter and the nine-month period ending December 31, 2025. This filing is a routine regulatory requirement under SEBI (LODR) Regulations to ensure transparency for all stakeholders. Investors can access the full recording through the company's dedicated investor relations web page.

Earnings call conducted on January 29, 2026, following the Q3 FY26 results announcement.
Recording covers financial performance for the nine-month period ended December 31, 2025.
Audio file is hosted on the company's official website under the Investor Relations section.
Compliance filing submitted under Regulation 30 of SEBI (LODR) Regulations, 2015.

💡 Investors should listen to the recording to understand management's perspective on loss ratios, premium growth, and the competitive landscape in the health insurance sector.

Niva Bupa Reports 74% YoY Profit Growth to ₹208.3 Cr for 9M FY26

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 29 Jan 2026, 07:19 PM

Niva Bupa Health Insurance reported a strong financial performance for the nine months ended December 31, 2025, with net profit surging 74% YoY to ₹20,831 Lakhs. Insurance revenue grew by 35.4% to reach ₹5,71,292 Lakhs, reflecting robust business expansion. Investment income also saw a significant jump of 43% to ₹47,804 Lakhs. While the growth is impressive, the company is currently awaiting IRDAI forbearance for exceeding Expenses of Management (EOM) limits for FY 2024-25.

Net Profit for 9M FY26 increased by 74.3% YoY to ₹20,831 Lakhs from ₹11,952 Lakhs.
Insurance revenue grew 35.4% YoY to ₹5,71,292 Lakhs compared to ₹4,21,786 Lakhs in the previous year.
Investment income rose to ₹47,804 Lakhs, a 43.1% increase over 9M FY25.
Basic Earnings Per Share (EPS) improved significantly to ₹1.13 from ₹0.69 YoY.
The company has applied for IRDAI forbearance regarding exceeding Expenses of Management (EOM) limits for FY 2024-25.

💡 The company demonstrates strong growth momentum in revenue and profitability; investors should maintain a positive outlook while monitoring the IRDAI's decision on management expense limits.

Niva Bupa Authorizes KMPs for Materiality Disclosures Under SEBI Regulations

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 29 Jan 2026, 06:44 PM

Niva Bupa Health Insurance has officially designated three Key Managerial Personnel (KMPs) to determine the materiality of events and information for stock exchange disclosures. This move is in compliance with Regulation 30(5) of the SEBI Listing Regulations. The authorized officials include the Managing Director & CEO, the Executive Director & CFO, and the Company Secretary. This is a standard administrative procedure for listed entities to ensure transparent and timely communication with investors.

Authorization of 3 Key Managerial Personnel (KMPs) for materiality determination under SEBI norms
Designated KMPs include Mr. Krishnan Ramachandran (MD & CEO) and Mr. Vishwanath Mahendra (ED & CFO)
Compliance with Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Contact details provided for investor queries via phone (+91-124-6354900) and email (investor@nivabupa.com)

💡 No action is required as this is a routine regulatory filing. Investors should maintain awareness of the designated contact points for future material company updates.

Niva Bupa Appoints Roger Davis as Director and Aparna Sharma as CS & Compliance Officer

🟢 POSITIVE ⭐ 7/10

MANAGEMENT 📅 29 Jan 2026, 06:41 PM

Niva Bupa Health Insurance has announced two key leadership appointments effective January 29, 2026. Mr. Roger William John Davis joins as an Additional Director, bringing 40 years of global financial services experience, including roles as Chairman of BUPA and Sainsbury’s Bank. Additionally, Ms. Aparna Sharma has been promoted to Company Secretary and Compliance Officer (KMP) after successfully overseeing the company's IPO execution. These appointments signify a strengthening of corporate governance and strategic oversight for the recently listed entity.

Appointment of Mr. Roger William John Davis as Additional Director with 40 years of global financial experience.
Mr. Davis previously served as Chairman of BUPA, Chairman of Sainsbury’s Bank, and on the Board of Barclays Bank PLC.
Ms. Aparna Sharma appointed as Company Secretary and Compliance Officer (KMP) effective January 29, 2026.
Ms. Sharma brings 15+ years of experience and was instrumental in the company's IPO and SEBI compliance implementation.
The board appointments are subject to member approval within three months.

💡 The addition of a high-caliber global leader from the BUPA group to the board is a positive signal for governance and strategic alignment. Investors should monitor how this leadership transition supports the company's post-IPO growth trajectory.

Niva Bupa Appoints Roger Davis as Non-Executive Director and Aparna Sharma as Company Secretary

🟢 POSITIVE ⭐ 7/10

MANAGEMENT 📅 29 Jan 2026, 06:39 PM

Niva Bupa Health Insurance has announced two significant leadership appointments effective January 29, 2026. Mr. Roger William John Davis joins as an Additional Non-Executive Director, bringing 40 years of global financial services experience, including former roles as Chairman of BUPA and Sainsbury’s Bank. Additionally, Ms. Aparna Sharma, who has over 15 years of experience in corporate governance and was instrumental in the company's IPO, has been appointed as Company Secretary and Compliance Officer. These appointments are expected to strengthen the company's governance framework and strategic oversight.

Appointment of Mr. Roger William John Davis as Additional Non-Executive Director effective January 29, 2026
Mr. Davis brings 40 years of experience, having served as Chairman of BUPA and on the Board of Barclays Bank PLC
Ms. Aparna Sharma appointed as Company Secretary and Compliance Officer (KMP) with 15+ years of experience
Mr. Davis previously held leadership roles including MD of India for Jardine Fleming and CEO of BZW Asia Pacific
Director appointment is subject to shareholder approval within three months from the date of appointment

💡 The addition of a high-profile international director like Roger Davis is a positive signal for the company's corporate governance and global strategic alignment. Investors should maintain a positive outlook on the stock as the company strengthens its leadership post-listing.

View All NIVABUPA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Gross Written Premium (GWP) grew by 20.59% YoY to reach INR 6,762.23 Cr in FY25. The bancassurance channel specifically grew by 24% YoY, contributing INR 1,359 Cr in premiums. Growth without the '1/N' accounting impact was reported at 32.1% for FY25.

Geographic Revenue Split

As of 6MFY24, revenue was distributed across Maharashtra (15.6%), Uttar Pradesh (10.9%), Delhi (9.5%), Karnataka (9.3%), Haryana (7.6%), Telangana (6.4%), and Gujarat (5.4%).

Profitability Margins

Profit After Tax (PAT) surged 160.8% YoY to INR 213.52 Cr in FY25 from INR 81.85 Cr in FY24. The Return on Net Worth (RONW) improved significantly from 3.99% to 6.98% during the same period. The Net Earnings Ratio stood at 3.98% in FY25 compared to 1.85% in FY24.

EBITDA Margin

Operating Profit Ratio was 3.68% in FY25, a decrease from 4.93% in FY24, primarily due to the transition to 1/n basis premium recognition. The combined operating ratio stood at 105.10% in FY25, slightly improved from 105.15% in FY24.

Capital Expenditure

The company significantly expanded its capital base by raising INR 800 Cr from investors including Temasek and Motilal Oswal, followed by an IPO that brought the paid-up share capital to INR 1,827.03 Cr as of March 31, 2025.

Credit Rating & Borrowing

CARE Ratings assigned a 'CARE A+; Stable' rating to the company's INR 250 Cr subordinate debt, upgraded from 'CARE A; Stable' due to a substantial increase in the capital base and a solvency ratio of 2.5x.

⚙️ Operational Drivers

Raw Materials

As an insurance provider, primary 'input' costs are Claims Incurred (Net) at INR 2,996.52 Cr (44.3% of GWP) and Commission Paid (Net) at INR 1,064.57 Cr (15.7% of GWP).

Import Sources

Not applicable for insurance services; sourcing relates to domestic distribution and healthcare provider networks across India.

Key Suppliers

Not applicable; the company partners with healthcare providers and distributors. It added 7 new bancassurance partners in FY25 to expand its distribution reach.

Capacity Expansion

The company expanded its physical footprint to 201 offices as of September 2023, up from 161 offices in March 2022. The investment book expanded to INR 8,175 Cr in FY25 from INR 5,458 Cr in FY24.

Raw Material Costs

Claims incurred (Net) rose 33% YoY to INR 2,996.52 Cr in FY25. The loss ratio increased to 61.2% in FY25 from 59.0% in FY24, impacting the combined ratio.

Manufacturing Efficiency

The Expense of Management (EOM) to Net Written Premium ratio was 49.39% in FY25. For H1 FY26, the EOM ratio was 36.3%, slightly above the regulatory limit of 35.8%.

Logistics & Distribution

Distribution is multi-channel; commission expenses increased to INR 1,064.57 Cr in FY25 from INR 748.18 Cr in FY24 to support a 20.59% growth in GWP.

📈 Strategic Growth

Expected Growth Rate

20.59%

Growth Strategy

Growth is driven by a multi-channel distribution strategy with a heavy emphasis on digital sales and bancassurance. The company added 7 new bank partners and is leveraging its association with Bupa Singapore Holdings (56% stake) for brand and strategic oversight.

Products & Services

Health insurance policies, including retail health, group health, and specialized health insurance products.

Brand Portfolio

Niva Bupa (formerly Max Bupa).

New Products/Services

Not disclosed in specific percentages, but the company focuses on diversified health insurance products across retail and group segments.

Market Expansion

Targeting increased market share in the Standalone Health Insurance (SAHI) segment, which improved to 17.59% in FY25 from 16.93% in FY24.

Market Share & Ranking

Overall health insurance market share increased to 5.31% in FY25 from 4.81% in FY24. Ranked as a leading Standalone Health Insurer (SAHI).

Strategic Alliances

Subsidiary of Bupa Singapore Holdings Pte. Limited (56% stake). Strategic investors include Temasek, Motilal Oswal, SBI Life, and Paragon.

🌍 External Factors

Industry Trends

The health insurance industry grew at 9.07% in FY25, while NBHI outpaced this at 20.59%. Trends include a shift toward digital distribution and regulatory shifts like the 1/n accounting method.

Competitive Landscape

Competes with other SAHIs (Standalone Health Insurers) and general insurance companies. NBHI holds a 17.59% share among SAHIs.

Competitive Moat

Moat is built on strong parentage (Bupa), a diversified distribution network (201 offices + bancassurance), and a high solvency ratio (2.5x) which allows for aggressive growth compared to peers.

Macro Economic Sensitivity

Highly sensitive to healthcare inflation and regulatory changes by IRDAI. Investment income (INR 479.83 Cr) is sensitive to interest rate cycles.

Consumer Behavior

Increasing demand for retail health insurance and digital-first purchase journeys.

Geopolitical Risks

Low direct impact as a domestic health insurer, though global parentage (Bupa UK) provides strategic stability.

⚖️ Regulatory & Governance

Industry Regulations

Subject to IRDAI regulations, including the 1/n accounting method for GWP and a 35% Expense of Management (EOM) limit. The company is currently at 36.3% EOM and aims to align by FY26 end.

Environmental Compliance

Exposure to environmental risks is low; the company has internal risk assessment mechanisms for ESG.

Taxation Policy Impact

Not disclosed as a specific percentage, but PAT was reported after tax provisions at INR 213.52 Cr.

Legal Contingencies

The company received a letter from the Insurance Regulatory and Development Authority of India (IRDAI) on November 12, 2025, regarding regulatory matters; specific case values were not disclosed.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the loss ratio, which rose to 61.2% in FY25. Regulatory compliance regarding EOM limits (currently 50 bps above limit) poses a compliance risk.